Rituximab in autoimmune bullous diseases: Mixed responses and adverse effects

British Journal of Dermatology

Volumn 156, Issue 2, 2007, Pages 352-356

  Schmidt, E ^a   Seitz, C S ^a   Benoit, S ^a   Brocker E B ^a   Goebeler, M ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoantibody; Bullous pemphigoid; Mucous membrane pemphigoid; Pemphigus; Therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; RITUXIMAB;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; BLINDNESS; BULLOUS PEMPHIGOID; BULLOUS SKIN DISEASE; CHILD; CLINICAL ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DRUG EFFICACY; ENTEROPATHY; FEMALE; HERPES ZOSTER; HUMAN; HYPOGAMMAGLOBULINEMIA; IMMUNOSUPPRESSIVE TREATMENT; LUNG EMBOLISM; MALE; MUCOUS MEMBRANE PEMPHIGOID; MULTIPLE CYCLE TREATMENT; PEMPHIGUS VULGARIS; PRIORITY JOURNAL; RNA VIRUS INFECTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; MOUTH DISEASES; MUCOUS MEMBRANE; NOSE DISEASES; PEMPHIGUS; TREATMENT OUTCOME;

EID: 33846204327     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07646.x     Document Type: Article

References (15)

1. Wojnarowska F, Kirtschig G, Highet AS et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147:214-21.
2. Harman KE, Albert S, Black MM. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149:926-37.
3. Chambers SA, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005; 14:210-14.
4. Schmidt E, Hunzelmann N, Zillikens D et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol 2006; 31:503-8.
5. Cooper HL, Healy E, Theaker JM, Friedmann PS. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol 2003; 28:366-8.
6. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol 2002; 47:785-8.
7. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol 2004; 51:817-19.
8. Schmidt E, Herzog S, Bröcker EB et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol 2005; 153:449-51.
9. Szabolcs P, Reese M, Yancey KB et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant 2002; 30:327-9.
10. Bennett CM, Rogers ZR, Kinnamon DD et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood 2006; 107:2639-42.
11. Willems M, Haddad E, Niaudet P et al. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006; 148:623-7.
12. Looney RJ, Anolik JH, Campbell D et al. B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004; 50:2580-9.
13. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572-81.
14. Schmidt E, Klinker E, Opitz A et al. Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus. Br J Dermatol 2003; 148:1222-9.
15. Leverkus M, Schmidt E, Lazarova Z et al. Anti-epiligrin cicatricial pemphigoid: an underdiagnosed entity within the spectrum of scarring subepidermal bullous diseases. Arch Dermatol 1999; 135:1091-8.